The First Drug for a Disease That Had Zero

Dr. Stephen Cederbaum, Professor Emeritus of Human and Medical Genetics at UCLA, called the approval "a major advancement in metabolic medicine," noting that it offers "a fundamentally new approach that addresses the enzyme deficiency itself."

The drug is approved for adults and children ages 2 and older and must be used alongside dietary protein restriction. It's not a replacement for the low-protein diet; think of it as a powerful new teammate, not a substitute for the whole squad.

The Trial That Got It Across the Finish Line

The approval hinged on the PEACE trial, a global, randomized, placebo-controlled Phase 3 study of 32 patients. In a disease this rare, enrolling 32 people is itself a small miracle of logistics and community trust.

The results were striking. After 24 weeks of weekly infusions, patients on pegzilarginase saw an 80% reduction in plasma arginine compared to placebo (p<0.0001). Even more telling: 90.5% of treated patients hit normal arginine levels, a threshold below 200 μmol/L. In the placebo group? Zero patients got there.

On the safety front, the drug was well tolerated. The most common side effects were vomiting, fever, and mild infusion reactions. Notably, no patients dropped out of the study due to adverse events, which is a strong signal for a chronic therapy people need to stick with long-term.

Now, one important caveat. This was an accelerated approval, meaning the FDA cleared it based on a surrogate endpoint (lower arginine levels) rather than waiting years to confirm that lower arginine translates into better long-term neurological outcomes. That confirmation is still coming; a post-marketing trial is required, with completion targeted for September 2034.

The FDA Threw Open Every Door

Loargys collected several important regulatory designations. Orphan Drug. Rare Pediatric Disease. Priority Review. Each designation is designed to speed up the path for drugs that treat serious conditions with unmet needs.

The BLA (biologics license application) was accepted for priority review in November 2024, and the approval came roughly 15 months later. For a rare disease program, that timeline is remarkably efficient.

When Can Patients Actually Get It?

This is where reality tempers the celebration. Despite the February approval, Loargys won't be commercially available until April 2026. Immedica Pharma, the Stockholm-based company behind the drug, is still setting up distribution and payer programs.

Pricing hasn't been publicly disclosed yet, but if history is any guide, we should expect a number that makes your eyes water. Enzyme replacement therapies for ultra-rare diseases routinely cost $200,000 to $500,000+ per year. With only a few hundred patients in the U.S., the math on recouping development costs forces prices into that stratosphere.

Anders Edvell, CEO of Immedica Pharma, pointed to the "collaborative efforts across the entire ARG1-D community including patients, advocacy groups, researchers, and clinicians" as essential to reaching this moment.

Why This Matters Beyond a Few Hundred Patients

It's easy to look at a drug for a few hundred Americans and wonder whether it moves the needle. But approvals like this one send a signal to the entire rare disease ecosystem.

The FDA also launched a new Plausible Mechanism Framework in 2026, designed to provide recommendations for generating evidence in ultra-rare disease approvals. Loargys arrives at a moment when regulators are actively rethinking how to evaluate drugs for diseases so small that traditional trial designs barely work.

For families who've spent years managing ARG1-D with protein restrictions and hope, April can't come soon enough. For the first time, their kitchen sink has a working drain.

The $381M Bet on Watching Proteins Move

Eikon Therapeutics just pulled off the largest biotech IPO in two years, raising $381 million on a platform that literally watches individual proteins move inside living cells. With Nobel Prize co-founder Eric Betzig and former Merck R&D chief Roger Perlmutter at the helm, the company is betting its cancer pipeline (and a billion-dollar war chest) on seeing biology differently.